Somatic Mutations in Exocrine Pancreatic Tumors: Association with Patient Survival

Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice

(2012) Meredith A. Collins et al.   JOURNAL OF CLINICAL INVESTIGATION

Increased Detection Sensitivity for KRAS Mutations Enhances the Prediction of Anti-EGFR Monoclonal Antibody Resistance in Metastatic Colorectal Cancer

(2011) F. Molinari et al.   CLINICAL CANCER RESEARCH

Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status

(2011) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of KRAS Mutations on Clinical Outcomes in Pancreatic Cancer Patients Treated with First-line Gemcitabine-Based Chemotherapy

(2011) S. T. Kim et al.   MOLECULAR CANCER THERAPEUTICS

Targeted treatment tested as potential cancer cure

(2011) Erika Check Hayden   NATURE

Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy

(2011) Eric A Collisson et al.   NATURE MEDICINE

Front-line therapy in lung cancer with mutations in EGFR

(2011) Lorenza Landi et al.   Nature Reviews Clinical Oncology

Targeted therapies: how personal should we go?

(2011) Miriam Martini et al.   Nature Reviews Clinical Oncology

BRAF targeted therapy changes the treatment paradigm in melanoma

(2011) Antoni Ribas et al.   Nature Reviews Clinical Oncology

Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer

(2010) Gilda da Cunha Santos et al.   CANCER

KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer

(2010) Wendy De Roock et al.   LANCET ONCOLOGY

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gene expression profiling identifies novel key players involved in the cytotoxic effect of Artesunate on pancreatic cancer cells

(2009) Mahmoud Youns et al.   BIOCHEMICAL PHARMACOLOGY

A Gene Expression Signature Associated with “K-Ras Addiction” Reveals Regulators of EMT and Tumor Cell Survival

(2009) Anurag Singh et al.   CANCER CELL

The angiotensin-I-converting enzyme inhibitor enalapril and aspirin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer

(2009) V. Fendrich et al.   GUT

KRAS2 Mutations in Human Pancreatic Acinar-Ductal Metaplastic Lesions Are Limited to Those with PanIN: Implications for the Human Pancreatic Cancer Cell of Origin

(2009) C. Shi et al.   MOLECULAR CANCER RESEARCH

COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer

(2009) Simon A. Forbes et al.   NUCLEIC ACIDS RESEARCH

Oncoproteomic profiling with antibody microarrays

(2009) Mohamed SS Alhamdani et al.   Genome Medicine

Pancreatic Cancer

(2008) Anirban Maitra et al.   Annual Review of Pathology-Mechanisms of Disease

Loss of Heterozygosity Predicts Poor Survival After Resection of Pancreatic Adenocarcinoma

(2008) Jan Franko et al.   JOURNAL OF GASTROINTESTINAL SURGERY

Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon

(2008) Kevin M Haigis et al.   NATURE GENETICS

Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses

(2008) S. Jones et al.   SCIENCE